This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters
by Kinjel Shah
J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.
Regeneron (REGN) Dupixent Gets FDA Nod for Asthma in Children
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Dupixent secures FDA approval to treat children aged 6-11 years with moderate to severe asthma.
Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.
4 Reasons to Add Regeneron (REGN) Stock to Your Portfolio
by Zacks Equity Research
Regeneron (REGN) is expected to gain from a solid and diverse portfolio despite stiff competition for its key drugs. The promising pipeline also sets the stage for growth further.
Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV
by Zacks Equity Research
Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.
The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi
Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More
by Kinjel Shah
Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.
AstraZeneca (AZN) to Buy Full Stake in Rare Disease Drugmaker
by Zacks Equity Research
AstraZeneca (AZN) looks to buy full stake in Caelum Biosciences to sharpen its focus on rare-disease drugs.
Perrigo (PRGO) Stock Up on Irish Tax Bill Settlement Deal
by Zacks Equity Research
Perrigo (PRGO) agrees to pay an aggregate of approximately $345 million (Euro 297 million) to settle its tax liability notice from the Irish Office of the Revenue Commissioners issued in 2018.
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
Top Research Reports for Microsoft, Amazon & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN), and NextEra Energy, Inc. (NEE).
Are Investors Undervaluing Sanofi (SNY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data
by Zacks Equity Research
Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.
Regeneron's (REGN) sBLA for Libtayo Gets Priority Review
by Zacks Equity Research
Regeneron's (REGN) application seeking the label expansion of PD-1 inhibitor Libtayo for the treatment of patients with recurrent or metastatic cervical cancer has been granted Priority Review.
Amgen (AMGN) Repatha Gets FDA Nod for Expanded Use in Kids
by Zacks Equity Research
FDA approves Amgen's (AMGN) Repatha for pediatric patients, 10 years of age and older, with familial hypercholesterolemia, both heterozygous and homozygous forms.
Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis
by Zacks Equity Research
Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.
Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe
by Zacks Equity Research
Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs
by Kinjel Shah
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.
Moderna (MRNA) Inks Vaccine Manufacturing Deal With Resilience
by Zacks Equity Research
Moderna (MRNA) is expanding its manufacturing and fill-finish capacities through collaborations deals with multiple companies to support the supply of its COVID-19 vaccine.
Perrigo (PRGO) to Acquire Another Self-Care Company HRA Pharma
by Zacks Equity Research
Perrigo (PRGO) offers to acquire HRA Pharma with several leading OTC brands in its portfolio for almost $2.1 billion. The acquisition will complete Perrigo's transformation into a leading self-care company.
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
by Zacks Equity Research
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.
Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate
by Zacks Equity Research
Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.
Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates
by Kinjel Shah
FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.
Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study
by Zacks Equity Research
GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.